Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H Buch

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Rheumatology (Oxford, England)|December 6, 2003
The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapyS J Bingham, M H Buch, A Tennant, et al.
Rheumatology (Oxford, England)|May 5, 2007
Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial respondersM H Buch, S J Bingham, D Bryer, et al.
Clinical and Experimental Rheumatology|July 17, 2009
Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaireG H Ibrahim, M H Buch, C Lawson, et al.
Annals of the Rheumatic Diseases|March 23, 2004
True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?M H Buch, P G Conaghan, M A Quinn, et al.
Annals of the Rheumatic Diseases|May 24, 2014
What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohortK Takase, S C Horton, A Ganesha, et al.
Arthritis and Rheumatism|February 5, 2010
Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatmentE M Vital, S Dass, A C Rawstron, et al.
Arthritis Research & Therapy|December 24, 2017
Profiling microRNAs in individuals at risk of progression to rheumatoid arthritisL Ouboussad, L Hunt, E M A Hensor, et al.
Rheumatology (Oxford, England)|July 29, 2008
The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)M H Buch, R J Reece, M A Quinn, et al.
Annals of the Rheumatic Diseases|April 7, 2009
Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation levelE Jones, S M Churchman, A English, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RAJ L Nam, K L Winthrop, R F van Vollenhoven, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Rheumatology (Oxford, England)|December 6, 2003
The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapyS J Bingham, M H Buch, A Tennant, et al.
Rheumatology (Oxford, England)|May 5, 2007
Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial respondersM H Buch, S J Bingham, D Bryer, et al.
Clinical and Experimental Rheumatology|July 17, 2009
Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaireG H Ibrahim, M H Buch, C Lawson, et al.
Annals of the Rheumatic Diseases|March 23, 2004
True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?M H Buch, P G Conaghan, M A Quinn, et al.
Annals of the Rheumatic Diseases|May 24, 2014
What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohortK Takase, S C Horton, A Ganesha, et al.
Arthritis and Rheumatism|February 5, 2010
Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatmentE M Vital, S Dass, A C Rawstron, et al.
Arthritis Research & Therapy|December 24, 2017
Profiling microRNAs in individuals at risk of progression to rheumatoid arthritisL Ouboussad, L Hunt, E M A Hensor, et al.
Rheumatology (Oxford, England)|July 29, 2008
The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)M H Buch, R J Reece, M A Quinn, et al.
Annals of the Rheumatic Diseases|April 7, 2009
Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation levelE Jones, S M Churchman, A English, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RAJ L Nam, K L Winthrop, R F van Vollenhoven, et al.
Pageof 2